How often does Cardiff Oncology move more than the options market prices?

0 of the last 8 reports moved at least as far as the implied move.

CRDFNasdaqBiological Products, (No Diagnostic Substances)

Cardiff Oncology, Inc. (CRDF) earnings date, market-implied expected move, and options open interest by expiry

0.85

−0.02 · −1.84%

post 0.88 +3.38%

Closed15:59 ET

Open0.90Volume224,953Mkt cap$67.1MEPS-0.60

Day0.87 – 0.9026%52-wk0.76 – 3.315%

CRDF

Cardiff Oncology, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Today

after close

est.Q3 FY26

Calendar

Next report

Last report

−5.67%

vs ±17.0% implied · ×0.33

shaded = implied · ▲▼ = realized

Aug 11 '26 · confirmed

Implied vs realized

Linked news

1dPFE · supplierPfizer names Cecile Guegan CFO; $1,300,000 base, $1,300,000 target incentive

News

Largest filed tie

13F top-10 QoQ

−13.27%

shares held · 10 largest managers

13F · Jun 30 '26128d lag

102 managers

Top fund weight

0.00%

CRDF weight · VTI

N-PORTJun 30 '26

1 fund

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Cardiff Oncology (CRDF) is expected to report on Nov 5 after close (estimated date).

Implied vs realized

8 reports

0 of 8≥ implied

avg implied: ±26.5%
avg realized: ±9.8%

Aug 8 '24Aug 8 '24confirmed±34.4%▲+11.74%×0.34

Nov 7 '24Nov 7 '24confirmed±37.4%▼−24.69%×0.66

Feb 27 '25Feb 27 '25confirmed±22.0%▲+4.43%×0.20

May 8 '25May 8 '25confirmed±15.4%▲+1.14%×0.07

Jul 29 '25Jul 29 '25confirmed±56.5%▼−24.77%×0.44

Q3 FY25Nov 6 '25confirmed±13.7%▼−2.67%×0.19

Q1 FY26May 14 '26confirmed±15.5%▼−3.47%×0.22

Q2 FY26Aug 11 '26confirmed±17.0%▼−5.67%×0.33

quarterimplied−60%0+60%realized×

Q2 FY26±17.0%▼−5.67%×0.33

Q1 FY26±15.5%

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 4 close

0.00OI · 4 expiries · Nov 4 closeP/C open interest · Nov 20 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

180%Nov 2015d4,7650%

0—Dec 1843d0.00297+194%0.00

680%Jan 1571d0.0014,6940%0.00

20%Feb 19106d0.011770%0.01

ExpiryPutsCallsP/C

Nov 2015d180%4,7650%0.00

Dec 1843d0—297+194%0.00

Jan 1571d680%14,6940%0.00

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ2 FY26

−8876.92%as filednet margin · revenue +153.66% QoQ · −14.05% YoY

Revenue$104,000+153.66%

Gross profit$104,000100.00%+153.66%

Operating income−$10M−9245.19%+25.18%

Pre-tax income−$9M+25.22%

Net income−$9M−8876.92%+25.22%

Cost of revenue$0—

Operating expenses$10M−24.61%

Other income$383,000−24.16%

Source: SEC filings · standardized · QE Jun 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

PPI ×1.95· ±7.8% vs ±4.0% · 10 releases

eventrelease day|move|up · n×base

PPIproducer prices±7.8%5 of 10×1.95

FOMCrate decision±5.4%10 of 24×1.35

GDPgross domestic product±5.1%8 of 19×1.27

CPROFcorporate profits±3.1%6 of 12×0.78

PCEpersonal income & outlays±2.9%10 of 19×0.71

NFPjobs report±2.4%5 of 10×0.59

CPIconsumer prices±2.3%3 of 10×0.58

Bar = avg |move| to ±8% · tick = ±4.0% avg day · ×base = |move| ÷ ±4.0% · min 6 releases

Earnings history

EPS -0.14 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 11 '26 · confirmed	-0.14	—
Q1 FY26	May 14 '26 · confirmed	-0.18	—
Q3 FY25	Nov 6 '25 · confirmed	-0.17	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod